BIOLASE Reports Landmark Head-to-Head Study Published in Journal of Periodontology Concludes That BIOLASE REPAIR® Perio Protocol is Superior for Procedure Time and Patient-Reported Outcomes

July 13, 2020

BIOLASE today announced data published in the Journal of Periodontology from a clinical trial conducted at The McGuire Institute. (The McGuire Institute is a not-for-profit organization with a unique vision for advancing the practice of dentistry through clinically-relevant research.)

BIOLASE reports, designed to meet the stringent American Association of Periodontology Best Evidence Consensus (BEC) standards, this first-of-its-kind study compared BIOLASE’s REPAIR® Perio protocol to the traditional Minimally Invasive Surgical Technique (MIST) treatment of moderate to severe generalized periodontitis.

The study found that the REPAIR Perio protocol had shorter procedure times than open flap procedures, as well as less bruising, swelling, and post-operative bleeding, demonstrating that REPAIR is as effective as open flap procedures in clinical parameters, such as pocket depth and attachment level, but with significantly better patient-reported outcomes.

“With 65 million Americans suffering from periodontitis, the findings from this study are significant in determining the best course of treatment for these patients,” said Todd Norbe, president and CEO of BIOLASE. “The study unequivocally confirms that patient-reported outcomes were significantly better after laser procedures. Using laser technology, periodontitis can now be treated – with less pain and greater patient acceptance – by both periodontists and general dentists alike. Studies continue to suggest that periodontal health is essential for overall health, as related to susceptibility to infection, including COVID-19 infections.”

BIOLASE believes this landmark study is the first controlled, multi-centered, blinded study on lasers in managing moderate to severe periodontitis. 54 patients were enrolled at five different sites, with six experienced periodontists.  It is also the only laser study in managing periodontitis designed to meet the stringent American Association of Periodontology BEC standards. To view the study results, visit here.

The REPAIR Perio protocol utilizes Waterlase® laser technology to provide safe, minimally invasive, effective laser treatment for periodontal disease.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version